Class 424/134.1 - Antibody, immunoglobulin, or fragment thereof fused via peptide linkage to nonimmunoglobulin protein, polypeptide, or fragment thereof (i.e., antibody or immunoglobulin fusion protein or polypeptide)

Subclass of Class 424 - Drug, bio-affecting and body treating compositions
Definition: Subject matter involving a fusion protein or fusion polypeptide
No. of patents: 509
Last issue date: 04/03/2012

«First «Previous1 2 3 4 5 6 7 8 9 10 11 Next»Last»

Number	Title	Issue Date
8148332	Method for treating a rheumatic disease using a soluble TLA4 molecule The present invention relates to compositions and methods for treating rheumatic diseases, such as psoriasis arthropathica, by administering to a subject a CTLA4 molecule that block endogenous B7 molecules from binding their ligands. ...	04/03/2012
8147835	Binding domain-immunoglobulin fusion proteins The invention relates to novel binding domain-immunoglobulin fusion proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, a wild-type IgG1, IGA or IgE hinge region polypeptide or a mutant IgG1 hinge region ...	04/03/2012
8142781	Fusion proteins for blood-brain barrier delivery The invention provides compositions, methods, and kits for increasing transport of agents across the blood brain barrier while allowing their activity once across the barrier to remain substantially intact. The agents are transported across the blood brain barrier v...	03/27/2012
8133487	Soluble heterodimeric cytokine receptor The present invention provides methods of treating psoriasis in a subject (i.e., psoriasis associated with a joint disease), by administering to the subject an effective dose of a composition comprising a soluble IL-22R/IL-20RB heterodimeric polypeptide, wherein the...	03/13/2012
8133866	Method for inhibiting new tissue growth in blood vessels in a patient subjected to blood vessel injury This invention provides for a method for inhibiting new tissue growth in blood vessels in a subject, wherein the subject experienced blood vessel injury, which comprises administering to the subject a pharmaceutically effective amount of an inhibitor of receptor for...	03/13/2012
8128931	Intrathecal and intratumoral superantigens to treat malignant disease The presence of tumor nodules in organs often results in serious clinical manifestations and the permeation by cancer cells of sheaths surrounding organs often produces clinical manifestations of pleural effusion, ascites or cerebral edema. The present invention add...	03/06/2012
8124084	Compositions and methods for immunomodulation in an organism using IL-15 and soluble IL-15Ra The present invention relates to a therapeutic polypeptide and methods for its creation and use for modulating an immune response in a host organism in need thereof. In particular, the invention relates to the administration to an organism in need thereof, of an eff...	02/28/2012
8092803	VEGF antagonist formulations for intravitreal administration Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulatio...	01/10/2012
8080245	Anti-pathogen immunoadhesins Chimeric molecules that include a pathogen recognition module derived from a pathogen binding domain of a pathogen recognition protein, e.g., a toll-like receptor (TLR), CD14, BPI, MD-2, scavenger receptors (SRs), surfactant proteins (SP), C-reactive protein (CRP), ...	12/20/2011
8080246	Colony stimulating factor 1 receptor (CSF1R) extracellular domain fusion molecules The present invention relates to specific CSF1R ECD fusion molecules that exhibit improved therapeutic properties. The invention also relates to polypeptide and polynucleotide sequences, vectors, host cells, and compositions comprising or encoding such molecules. Th...	12/20/2011
8071095	Immunosuppressive polypeptides and nucleic acids The invention provides immunosuppressive polypeptides and nucleic acids encoding such polypeptides. In one aspect, the invention provides mutant CTLA-4 polypeptides and nucleic acids encoding mutant CTLA-4 polypeptides. Compositions and methods for utilizing such po...	12/06/2011
8048418	Therapeutic methods for inhibiting tumor growth with combination of Dll4 antagonists and VEGF antagonists Disclosed is a therapeutic method for inhibiting development or growth of tumors that are resistant to the blockade of delta-like ligand 4 (Dll4), or vascular endothelial growth factor (VEGF), or to other therapeutic agents, by administering the combination of Dll4 ...	11/01/2011
8048417	Anti-human tenascin monoclonal antibody A novel anti-human tenascin ST2146 monoclonal antibody is described endowed with high affinity with the native antigen and high tumor selectivity. The cST2146 hybridoma is stably producing the antibody in high density culture conditions and is suitable for the indus...	11/01/2011
8043616	sRAGE mimetibody, compositions, methods and uses Mammalian sRAGE mimetibody polypeptides and nucleic acids are disclosed. Methods of utilizing the polypeptides to reduce or inhibit the binding of RAGE and its ligands and to treat RAGE-related diseases are also disclosed. ...	10/25/2011
8029791	Modified chimeric polypeptides with improved pharmacokinetic properties Modified chimeric polypeptides with improved pharmacokinetics are disclosed. Specifically, modified chimeric Flt1 receptor polypeptides that have been modified in such a way as to improve their pharmacokinetic profile are disclosed. Also disclosed are methods of mak...	10/04/2011
8012479	Recombinant toxin fragments Antigenic compositions are provided comprising a single chain polypeptide comprising first and second domains, wherein said first domain is a clostridial neurotoxin light chain or a fragment or a variant thereof and is capable of cleaving one or more vesicle or plas...	09/06/2011
7981417	Blood-brain barrier targeting anti-bodies This invention provides antibodies that bind brain endothelial cell receptors resulting in endocytosis/transcytosis of the receptor and bound ligands. In some embodiments, the ligand comprises the antibody in combination with a pharmaceutically active compound and t...	07/19/2011
7977314	Methods and compositions to treat and detect misfolded-SOD1 mediated diseases The invention provides a method for treating a medical condition, disease, or disorder mediated by a misfolded form of superoxide dismutase (SOD) in a subject in need of treatment. The method optionally comprises administering to the subject a composition comprising...	07/12/2011
7972598	VEGF-binding fusion proteins and therapeutic uses thereof Fusion proteins which bind and inhibit vascular endothelial growth factor (VEGF). The VEGF-binding fusion proteins are therapeutically useful for treating VEGF-associated conditions and diseases, and are specifically designed for local administration to specific org...	07/05/2011
7968091	Methods and compositions to regulate iron metabolism The present invention provides new systems and strategies for the regulation of iron metabolism in mammals. In particular, methods of using agonists and antagonists of TGF-β superfamily members to modulate the expression or activity of hepcidin, a key regulator of ...	06/28/2011
7951371	Soluble lymphotoxin-β receptor fusion protein and methods for inhibiting lymphotoxin β-receptor signaling This invention relates to compositions and methods comprising “lymphotoxin-β-receptor blocking agents”, which block lymphotoxin-β receptor signalling. Lymphotoxin-β receptor blocking agents are useful for treating lymphocyte-mediated immunological diseases, a...	05/31/2011
7943133	Mesothelin antibody protein fusions and methods of use The invention relates to fusion proteins comprising a stress protein fused with an engineered antibody or fragment that binds to mesothelin, or a stress protein fused with a biotin-binding protein in combination with a biotinylated engineered antibody or fragment th...	05/17/2011
7939071	Artery- and vein-specific proteins and uses therefor Arterial and venous endothelial cells are molecularly distinct from the earliest stages of angiogenesis. This distinction is revealed by expression on arterial cells of a transmembrane ligand, called EphrinB2 whose receptor EphB4 is expressed on venous cells. Target...	05/10/2011
7931900	Method for the treatment of multiple sclerosis by inhibiting IL-17 activity The present invention provides a method for the treatment and/or prophylaxis of multiple sclerosis (MS) comprising administering a therapeutically effective amount of an inhibitor of IL-17 activity. ...	04/26/2011
7910102	Methods of using conjugated toxin peptide therapeutic agents Disclosed is a composition of matter comprising an OSK1 peptide analog, and in some embodiments, a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises the composition and a pharmaceutically acceptable carrier. Also disclosed are DNAs enc...	03/22/2011
7910101	Melanocortin receptor binding mimetibodies, compositions, methods and uses Melanocortin receptor binding mimetibody polypeptides are disclosed. Polynucleotides encoding these polypeptides, cells comprising these polynucleotides or expressing the mimetibodies, and methods of making and using the forgoing are also disclosed. ...	03/22/2011
7906118	Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (DNL) technology The present invention concerns methods and compositions for forming cytokine-antibody complexes using dock-and-lock technology. In preferred embodiments, the cytokine-MAb DNL complex comprises an IgG antibody attached to two AD (anchor domain) moieties and four cyto...	03/15/2011
7901680	Dock-and-lock (DNL) vaccines for cancer therapy The present invention concerns methods and compositions for forming anti-cancer vaccine DNL complexes using dock-and-lock technology. In preferred embodiments, the anti-cancer vaccine DNL complex comprises an antibody moiety that binds to dendritic cells, such as an...	03/08/2011
7879324	Fusion molecules and methods for treatment of immune diseases The invention concerns bifunctional fusion molecules, and novel, safer and more efficacious methods for the treatment of immune disorders resulting from excessive or unwanted immune responses. The invention provides methods for the suppression of type I hypersensiti...	02/01/2011
7846438	Methods of promoting neurite outgrowth with soluble TAJ polypeptides The invention provides methods of treating diseases, disorders, injuries, or conditions involving modulating neurite outgrowth and/or survival, including CNS disorders, stroke, or spinal injury, by administration of a TAJ antagonist. ...	12/07/2010
7820165	Compositions and methods of producing hybrid antigen binding molecules and uses thereof This disclosure relates to hybrid antigen binding molecules including at least two polypeptide chains, with at least one polypeptide chain comprises an antigen binding moiety linked to an amino acid sequence of a subunit of a heterodimeric proteinaceous hormone. Als...	10/26/2010
7807164	Lyophilized VEGF antagonist formulations for intravitreal administration Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulatio...	10/05/2010
7794718	Immunosuppressive polypeptides and nucleic acids The invention provides immunosuppressive polypeptides and nucleic acids encoding such polypeptides. In one aspect, the invention provides mutant CTLA-4 polypeptides and nucleic acids encoding mutant CTLA-4 polypeptides. Compositions and methods for utilizing such po...	09/14/2010
7771721	Methods for using chimeric vascular endothelial growth factor receptor proteins The present invention is directed to novel chimeric VEGF receptor proteins comprising amino acid sequences derived from the vascular endothelial growth factor (VEGF) receptors flt-1 and KDR, including the murine homologue to the human KDR receptor FLK-1, wherein sai...	08/10/2010
7754211	Immunotoxins directed against c-erbB-2(HER-2/neu) related surface antigens Novel immunotoxins and methods of treating neoplastic diseases are provided. More specifically, immunotoxins comprised conjugation of a c-erbB-2 targeting moiety and a cell growth modulator are provided. These immunotoxins specifically and selectively kill tumor cel...	07/13/2010
7718176	Human EPO mimetic hinge core mimetibodies, compositions, methods and uses The present invention relates to at least one human EPO mimetic hinge core mimetibody or specified portion or variant, including isolated nucleic acids that encode at least one EPO mimetic hinge core mimetibody or specified portion or variant, EPO mimetic hinge core...	05/18/2010
7704500	Methods of inhibiting ascites formation with modified chimeric VEGF polypeptides Modified chimeric polypeptides with improved pharmacokinetics are disclosed. Specifically, modified chimeric Flt1 receptor polypeptides that have been modified in such a way as to improve their pharmacokinetic profile are disclosed. Also disclosed are methods of mak...	04/27/2010
7700100	FcγRIIB fusion proteins and compositions thereof The present invention relates to molecules, preferably soluble (i.e., not membrane bound) polypeptides, most preferably soluble fusion polypeptides comprising the extracellular soluble regions of FcγRIIB, derivatives and analogs thereof, and nucleic acids encoding ...	04/20/2010
7670602	Concatameric immunoadhesion molecule Disclosed are concatameric proteins comprising two soluble domains, in which the C-terminus of a soluble domain of a biologically active protein is linked to the N-terminus of an identical soluble domain or a distinct soluble domain of a biologically active protein....	03/02/2010
7666416	Mammalian cell culture process The present invention relates to novel process for the preparation of glycoproteins by mammalian-cell culture wherein the sialic acid content of the glycoprotein' produced is controlled over a broad range of values by manipulating the cell culture environment. The i...	02/23/2010

«First «Previous1 2 3 4 5 6 7 8 9 10 11 Next»Last»

PatentStorm

Bizarre Patents

PatentStorm News

Class 424/134.1 - Antibody, immunoglobulin, or fragment thereof fused via peptide linkage to nonimmunoglobulin protein, polypeptide, or fragment thereof (i.e., antibody or immunoglobulin fusion protein or polypeptide)